Forensic Analysis · Industrial & Scientific Instruments · as of Nov 8, 2026
Bruker Corp (BRKR)
A forensic read on Bruker Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
B · Sound & dependable
Forensic grade
Safe
Financial health
3.0
Distress distance
Clean
Earnings quality
3
Forensic signals
-0.4%
ROE
2.1%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Bruker Corp earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 3.0, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
1.0%
FY2025
Return on invested capital.Return on invested capital is 1.0% in the latest fiscal year and slipping across FY2023–FY2025 from 12.8%. After-tax operating profit was $342M in FY2023 and $44M in FY2025, with operating income at 14.7% of revenue in FY2023, 7.5% in FY2024 and 2.0% in FY2025. The capital base behind it grew +69% across FY2023–FY2025, from $2.7B to $4.5B, while the return fell 11.8 points, so the dollars added over that window earned less than the 12.8% the older base was already earning. FY2025's operating profit carried a $96M goodwill write-off, a $77M restructuring charge and a $31M asset write-down that alone took about 2.9 points off that year's return, so about 2.9 of the 11.8-point fall across FY2023–FY2025 is that charge landing in the latest year rather than the capital earning less. FY2024's operating profit carried a $28M asset write-down and a $25M restructuring charge that alone took about 1.0 points off that year's return; FY2024 sits between the two ends of FY2023–FY2025, so the charge shapes the path between them without moving the change across it. A non-cash write-down lowers the reported return in the year it lands.
$96M
FY2025
Goodwill impairments.Took $96M of goodwill writedowns across 1 year (FY2025 ($96M)). Writedowns mean past acquisitions underperformed what was paid for them.
-26%
FY2024→FY2025
Dividend — cut.The payout was CUT ~26% in FY2025 (from FY2024). It still returns some cash, but it is NOT the dependable, rising dividend an unbroken streak implies.
Key fundamentals
Latest Revenue$3.44B
Revenue Growth YoY+2.1%
Revenue CAGR (2yr)+7.7%
Net Margin-0.3%
Free Cash Flow$43.3M
Return on Equity-0.4%
Debt / Equity0.76x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Bruker Corp's actual 10-K/10-Q/8-K filings?